Is PT-141 (Bremelanotide) Legal in Missouri?

HealthRX.com

Vyleesi is FDA-approved; compounded PT-141 is not

40.0%Share of Vyleesi users with nausea, versus 1.3% on placeboSource: dailymed.nlm.nih.gov

Print or save as PDF

Key numbers

  • 1.75 mgApproved Vyleesi strength, given as a prefilled subcutaneous autoinjectorSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 40.0%Share of Vyleesi users with nausea, versus 1.3% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 6 mmHgMaximal systolic blood pressure rise after one Vyleesi doseSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 1%Share of patients on up to 8 doses a month with focal hyperpigmentation, versus none on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Bremelanotide

  • Federal status / Prescription drug, approved as Vyleesi, NDA 210557, June 21, 2019 [1][2]
  • Approved indication / Acquired, generalized HSDD in premenopausal women [1]
  • Not approved for / Men, postmenopausal women, or enhancing sexual performance [1]
  • Boxed warning / None [1]
  • Compounded PT-141 / Not an FDA-approved drug; not reviewed by FDA before marketing [3]
  • FDA bulk-substance lists / Bremelanotide in no category [4]

Is PT-141 legal in Missouri?

Vyleesi is the FDA-approved bremelanotide product: 1.75 mg in a prefilled subcutaneous autoinjector, prescription only, approved June 21, 2019 under NDA 210557 and now held by Cosette Pharmaceuticals [1][2][5]. Its approved use is premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD): low sexual desire that causes marked distress or interpersonal difficulty and is not due to a coexisting medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label says it is not indicated for postmenopausal women, for men, or to enhance sexual performance [1].

Questions worth asking

Choose the questions you want to keep

What is actually sold as PT-141

Compounded bremelanotide is not an FDA-approved drug, and FDA does not review compounded drugs for safety, effectiveness or quality before they reach patients [3]. A vial sold as a research-use peptide is not Vyleesi and is not an approved drug product [6].

Bremelanotide appears in no category on FDA's bulk-substance lists and is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [4][7].

What the label says to watch for

The label lists uncontrolled hypertension or known cardiovascular disease as contraindications and says Vyleesi is not recommended for people at high cardiovascular risk [1]. Each dose raises blood pressure briefly: maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with heart rate down up to 5 beats per minute and values usually back to baseline within 12 hours [1]. Nausea occurred in 40.0% versus 1.3% on placebo, with 13% needing an anti-nausea medicine and 8% stopping [1]. Focal hyperpigmentation, including the face, gums and breasts, was reported by 1% of patients taking up to 8 doses a month versus none on placebo [1]. The label says to avoid Vyleesi with oral naltrexone products intended to treat alcohol or opioid addiction [1]. There is no boxed warning [1].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. According to the article, what is the approved use for Vyleesi?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Is PT-141 legal in Missouri?
Vyleesi, the FDA-approved form of bremelanotide, is a prescription-only drug under federal approval that applies nationwide [1][2]. PT-141 sold as a compounded or research-use peptide is not Vyleesi and is not an FDA-approved drug [3][6].
Is PT-141 FDA-approved?
Yes, as Vyleesi: a 1.75 mg subcutaneous autoinjector approved June 21, 2019 under NDA 210557 [1][2]. The label says it is not indicated for men, for postmenopausal women, or to enhance sexual performance [1].
Does Vyleesi have a boxed warning or a REMS?
Neither. The label has no boxed warning, and no REMS appears in the label or the 2019 approval letter [1][2].
Is compounded or research-use PT-141 an approved drug?
No. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before marketing [3]. Vyleesi is the approved product [1]. Bremelanotide appears in no category on FDA bulk-substance lists [4].
What are the common side effects of bremelanotide?
In the pooled adverse-reaction analysis, 627 women received Vyleesi and 620 received placebo; the two trials randomized 1,267 women overall [1][8]. Nausea occurred in 40.0% versus 1.3% on placebo, flushing 20.3% versus 0.3%, injection site reactions 13.2% versus 8.4% and headache 11.3% versus 1.9% [1].
Show all 8 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
  2. U.S. Food and Drug Administration.
  3. Human Drug Compounding Laws | FDA.
  4. U.S. Food and Drug Administration.
  5. Drugs@FDA: FDA-Approved Drugs.
  6. Official web page.
  7. Official web page.
  8. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.
PT-141 Missouri: evidence summary chart
Image: HealthRX.com. Full PT-141 Missouri guide and sources at healthrx.com/peptide-legal-pt-141.